Lasofoxifene,Fulvestrant
Sermonix,pfizer
['mbc', 'medsir']
great talk by on elaine 1 trial showing the activity of the novel serm lasofoxine in pts with er+/her2-/esr1-mutated mbc with progression on cdk4/6i. although without statistically significance, all clinical outcomes numerically favored lasofoxine vs. fluvestrant #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM